Phase 3
N=713
Heart And Lung Failure - Pediatric INsulin Titration Trial
Heart Failure · Respiratory Failure
Bottom Line
View on ClinicalTrials.gov: NCT01565941 ↗Enrolled (actual)
713
Serious AEs
3.6%
Results posted
Dec 2017
Primary outcome: Primary: ICU-Free Days — 20; 19.4 Days
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Insulin (Drug)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Boston Children's Hospital
- Primary completion
- Sep 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ICU-Free Days |
20; 19.4 | — |
| SECONDARY 90-day Hospital Mortality |
52; 40 | — |
| SECONDARY 28-day Hospital Mortality |
47; 32 | — |
| SECONDARY Accumulation of Multiple Organ Dysfunction Syndrome (MODS) |
326; 324 | — |
| SECONDARY Ventilator-Free Days |
21.8; 20.9 | — |
| SECONDARY Developmental Neurobehavioral Outcomes: VABS-II Composite |
79.9; 79.4 | — |
| SECONDARY Participants With Device-Related or Non-Device Related Nosocomial Infection |
12; 4 | — |
| SECONDARY Incidence of Catheter-Associated Bloodstream Infection |
1.94; 0 | — |
| SECONDARY Incidence of Catheter-Associated Urinary Tract Infection |
2.19; 1.79 | — |
| SECONDARY Incidence of Ventilator-Associated Pneumonia |
0.94; 0 | — |
| SECONDARY Incidence of Wound Infection Incidence of Wound Infection |
0; 0 | — |
| SECONDARY Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) |
5; 6 | — |
| SECONDARY Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) |
13; 1 | — |
| SECONDARY Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) |
26; 29 | — |
| SECONDARY Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) |
64; 5 | — |
| SECONDARY Participants With Hypokalemia (<2.5 mmol/L) |
76; 64 | — |
| SECONDARY Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument |
50.0; 36.2 | — |
| SECONDARY Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument |
35.0; 20.4 | — |
| SECONDARY Insulin Algorithm Performance: Time to the Target Range |
5.5; 1.5 | — |
| SECONDARY Insulin Algorithm Performance: Time in the Target Range |
57; 91 | — |
| SECONDARY Insulin Algorithm Performance: Time-Weighted Glucose Average |
109; 123 | — |
Summary
Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical patients but has since come under intense scrutiny due to conflicting results in recent adult trials. One pediatric RCT has been published to date that demonstrated survival benefit but was complicated by an unacceptably high rate of severe hypoglycemia. The Heart And Lung Failure - Pediatric INsulin Titration (HALF-PINT) trial is a multi-center, randomized clinical treatment trial comparing two ranges of glucose control in hyperglycemic critically ill children with heart and/or lung failure. Both target ranges of glucose control fall within the range of "usual care" for critically ill children managed in pediatric intensive care units.
The purpose of the study is to determine the comparative effectiveness of tight glycemic control to a target range of 80-110 mg/dL (TGC-1, 4.4-6.1 mmol/L) vs. a target range of 150-180 mg/dL (TGC-2, 8.3-10.0 mmol/L) on hospital mortality and intensive care unit (ICU) length of stay (LOS) in hyperglycemic critically ill children with cardiovascular and/or respiratory failure. This will be accomplished using an explicit insulin titration algorithm and continuous glucose monitoring to safely achieve these glucose targets. Both groups will receive identical standardized intravenous glucose at an age-appropriate rate in order to provide basal calories and mitigate hypoglycemia. Insulin infusions will be titrated with an explicit algorithm combined with continuous glucose monitoring using a protocol that has been safely implemented in 490 critically ill infants and children.
Eligibility Criteria
Inclusion Criteria
- Cardiovascular failure and/or respiratory failure:
- Cardiovascular Failure: Dopamine or dobutamine > 5 mcg/kg/min, or any dose of epinephrine, norepinephrine, phenylephrine, milrinone or vasopressin if used to treat hypotension.
- Respiratory Failure: Acute mechanical ventilation via endotracheal tube or tracheostomy.
- Age >= 2 weeks and corrected gestational age >= 42 weeks
- Age 28 days
- Receiving therapeutic cooling with targeted body temperatures <34 degrees Celsius
- Current or planned ketogenic diet
- Ward of the state
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT01565941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.